Navigation Links
Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010
Date:2/10/2011

gyProprietary OncologyTREANDA393,473-393,473222,112-222,11277-77Other Proprietary Oncology20,86676,25697,12218,28175,36093,6411414Generic Oncology-22,99822,998-20,94020,940-1010Oncology414,33999,254513,593240,39396,300336,69372353OtherOther Proprietary15,1125,80920,92117,545-17,545(14)10019Other Generic13,220292,562305,78215,436108,922124,358(14)169146Other28,332298,371326,70332,981108,922141,903(14)174130$ 2,102,175$ 658,777$ 2,760,952$ 1,768,383$ 383,165$ 2,151,54819%72%28% Europe- Primarily Europe, Middle East and Africa Proprietary products are products which are sold under patent coverage.   Generic products are products sold without patent coverage in the primary sales territory. Patent coverage may exist in other territories.   CEPHALON, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(In thousands, except share data)(Unaudited) December 31, 20102009CURRENT ASSETS:   Cash and cash equivalents

$ 1,160,239$ 1,647,635   Receivables, net

431,333376,076   Inventory, net

291,360240,576   Deferred tax assets, net

213,798243,246   Other current assets

54,84558,423Total current assets

2,151,5752,565,956   INVESTMENTS ($155,808 at fair value in 2010)

168,49412,427   PROPERTY AND EQUIPMENT, net

502,856451,879   GOODWILL

822,071590,284   INTANGIBLE ASSETS, net

1,212,387981,857   DEBT ISSUANCE COSTS

14,19618,862   OTHER ASSETS

20,25436,830$ 4,891,833$ 4,658,095CURRENT LIABILITIES:   Current portion of long-term debt, net

$
51,997$
818,925   Accounts payable

104,47788,829   Accrued expenses

460,141430,209Total current liabilities

1,216,6151,337,963   LONG-TERM DEBT

391,416363,696   DEFERRED TAX LIABILITIES, net

172,589159,328   OTHER LIABILITIES

273,438111,728Total liabilities

2,054,0581,972,715REDEEMABLE EQUITY

170,183207,307E
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
2. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
3. Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder
4. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
5. Cephalon to Webcast Investor Day
6. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
7. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
8. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
9. Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
10. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
11. Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... MOUNTAIN VIEW, Calif. , Oct. 22, ... 11:00 a.m. EDTLOCATION: Online, complimentary registration available ... Group Team Leader Archana Vidyasekar and Visionary ... VargheseBrain-controlled computers, WiFi-like wireless electricity, self-assembling materials, ... top ten technologies which will transform our ...
(Date:10/22/2014)... -- Recently published clinical studies of Stretta for gastroesophageal reflux ... evidence. This data has led to significantly expanded insurance ... sufferers of refractory GERD. The substantial ... as a safe and effective GERD treatment has driven ... nearly 50 million Americans. The new clinical studies include; ...
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... Mitsubishi Chemical Medience Corporation announced today that the ... 510(k) premarketing notification clearance to the PATHFAST® cTnI-II ... for its sale in the United States. The ... PATHFAST analysis system, a unique, self-contained, bench-top chemi-luminescence ...
... Reportlinker.com announces that a new market research ... Distributor Analysis of the Pharmaceutical ... http://www.reportlinker.com/p0552921/Distributor-Analysis-of-the-Pharmaceutical-Industry-in-Key-SADC-Countries.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceu ... to present an overview of the pharmaceutical ...
Cached Medicine Technology:Mitsubishi Chemical Medience Corporation Receives 510(k) Clearance for PATHFAST® cTnI-II (cardiac Troponin I) Test in U.S. 2Mitsubishi Chemical Medience Corporation Receives 510(k) Clearance for PATHFAST® cTnI-II (cardiac Troponin I) Test in U.S. 3Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 2Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 3
(Date:10/22/2014)... (PRWEB) October 22, 2014 The ... , which is dedicated to distribute health information ... healthcare delivery worldwide announced the development of six ... patients expect when receiving healthcare. These are an ... patient-centered care: “providing care that is respectful of ...
(Date:10/22/2014)... 2014 With the Affordable Care Act (ACA) ... the American Institutes for Research (AIR) finds that three out ... health insurance, but 42 percent say they are not likely ... signing up for coverage. , The AIR survey found wide ... able to calculate correctly how much they owe for a ...
(Date:10/22/2014)... October 22, 2014 Best Cheap Hosting ... the world. The site has recently announced that iPower ... supplier for people from around the world. , “iPower ... operation today and is providing various kinds of useful ... company insists on offering excellent customer service and a ...
(Date:10/22/2014)... 22, 2014 Losing Weight Your Body’s Way ... staring you in the face, it certainly can be difficult ... your body an extra favor by doing it the healthy ... diets. Instead, listen to your body, exercise regularly, and choose ... essential to losing weight; you need to exercise more and ...
(Date:10/22/2014)... Lintelus, Inc., an event software provider, ... Sales, will be speaking on the subject of “Event ... October 28, at the Holiday Inn in New York ... well as a Tech Demo at 12:45pm, to educate ... more engaging event experience. , The Annual Meetings Technology ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
... Strike Anyone, Anywhere; Urges Americans to Work With CPF to ... (PF) claims a life every 13 minutes in the U.S., ... cancer; yet most Americans have never heard of the disease ... Coalition for Pulmonary Fibrosis (CPF) today launched a new public ...
... techniques, the accuracy of preoperative rectal cancer staging has ... rectal cancer patients has become a very important aim ... published on March 14, 2009 in the World ... 5-year survival after local excision of rectal cancer, and ...
... of Nicotine and Tobacco Research Analyzes Trends, Impact of ... majority of research conducted about tobacco use has been ... The March 2009 issue of Nicotine and ... intermittent smoking. Several of the nation,s preeminent public health ...
... works for some people might be dangerous for others, ... confirmed previously reported genetic factors that may help doctors ... thinner warfarin to people at high risk of cardiovascular ... Administration estimates, about 2 million Americans use the anticoagulant ...
... Shire plc (LSE: SHP, Nasdaq: SHPGY ), ... market withdrawal/recall of thirty-nine (39) lots of the ADHD ... this action are listed below). Shire is taking ... their release liner removal specification, and as a result, ...
... campaign which will reduce mortality in patients with acute ... which includes the ESC Working Group on Acute Cardiac ... (EAPCI). "Stent 4 Life" is a project designed to ... coronary interventions (PCI, with balloon angioplasty and stent) in ...
Cached Medicine News:Health News:CPF Launches National PSA to Educate Public on Pulmonary Fibrosis 2Health News:CPF Launches National PSA to Educate Public on Pulmonary Fibrosis 3Health News:New Analysis: Light and Intermittent Smokers Overlooked in Traditional Tobacco Research 2Health News:New Analysis: Light and Intermittent Smokers Overlooked in Traditional Tobacco Research 3Health News:New Analysis: Light and Intermittent Smokers Overlooked in Traditional Tobacco Research 4Health News:Genetics Should Decide Warfarin Dose, Study Reiterates 2Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 2Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 3Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 4Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 5Health News:'Stent 4 Life': A campaign is launched to increase the use of primary PCI in acute coronary patients 2
... OptiMumm™ smoke evacuator is ... complete smoke evacuation system ... AccuVac™ smoke evacuation attachment, ... and either the Force ...
Turnstile casting stand for easy and safe casting. The compact system sets up quickly and stores conveniently, and the non-stick coating prevents fiberglass or plaster from adhering to surface....
Bone cement with Gentamicin 2.5%....
... Techno-Aide provides the highest level ... highest quality lead protective eyewear. ... + tolerance allowed. Mfg supervised by ... All lens meet or exceed standards ...
Medicine Products: